Oxford starts recruiting to 100,000 Genomes Project
The Oxford NHS Genomic Medicine Centre (GMC) is one of 11 Genomic Medicine Centres delivering the 100,000 Genomes Project across England. Oxford GMC is the first to begin recruiting patients to the main cancer phase of the project.
More than 1,200 patients and their families who are looked after by the Oxford University Hospitals NHS Trust (OUHT) will take part. Eligible patients with rare diseases and cancers are being invited to provide health data and blood and tissue samples for whole genome sequencing – where a complete set of a person’s genes is decoded – for the 100,000 Genomes Project. Samples will also be taken for other type of analyses for further research and extensive clinical outcome data will be collected. The project will aid research, improve diagnosis and ultimately clinical outcomes for patients.
Oxford NHS GMC clinicians will have access to results for validation and clinical action. By providing information about each disease’s unique genetic code, it is hoped that patients will benefit from treatment tailored to their needs. The information captured will also be available to researchers for ethically approved research, to help develop new knowledge and treatments.
Director of the Oxford NHS Genomic Medicine Centre and Associate Professor of Molecular Diagnostics for the University’s Department of Oncology Anna Schuh said: “Oxford University Hospital NHS Trust’s designation as a Genomic Medicine Centre will allow eligible patients with rare diseases and their families and patients suffering from cancers to gain equitable access to state-of-the-art genomic diagnostics.
“For some of these patients, this new diagnostic approach will alter clinical management and can guide clinicians towards more effective treatment options. At the same time, by helping to recruit thousands of patients to this unique programme across England, we will make a significant contribution to collaborative research aimed at improving our understanding of these diseases which will ultimately lead to successful design of new therapies.”
Read more in the Oxford Mail.